TABLE 3.
Survival of patients in modified intent‐to‐treat population (n = 79) and in subgroups of interest (median follow‐up, 44 months).
| N | Survival | ||||
|---|---|---|---|---|---|
|
Median (months) |
95% CI | 24 months (%) |
36 months (%) |
||
| Progression‐free survival | |||||
| ≥2 HDCT cycles a | 79 | 12.3 | 7.5–25.9 | 40.4 | 37.6 |
| ≥3 HDCT cycles | 70 | 12.5 | 7.6–28.1 | 41.3 | 38.2 |
| CR or PR with negative tumor markers | 55 | NR | ‐ | 56.3 | 52.1 |
| High/very high‐risk b or ≥2nd line (≥2 HDCT cycles) | 51 | 8.4 | 6.5–NR | 41.1 | 38.8 |
| Overall survival | |||||
| ≥2 HDCT cycles a | 79 | 46.3 | 18.6–NR | 55.0 | 50.1 |
| ≥3 HDCT cycles | 70 | 46.3 | 18.6–NR | 56.3 | 50.9 |
| CR or PR with negative tumor markers | 55 | NR | ‐ | 70.6 | 63.8 |
| High/very high‐risk b or ≥2nd line (≥2 HDCT cycles) | 51 | 26.8 | 12.9–NR | 50.2 | 47.9 |
Abbreviations: CR, complete response; HDCT, high‐dose chemotherapy; NR, not reached; PR, partial response.
a
Modified intent‐to‐treat population
b
International prognosis score for patients with one line of metastatic chemotherapy.